[Evaluation of prednisone treatment in children with IgA nephropathy and Schönlein-Henoch nephropathy according to the Waldo protocol with regard to pathomorphologic changes in renal biopsy].
The aim of the study was to analyse effectiveness of long term alternate-day prednisone treatment according the protocol of Waldo (Pediatr. Nephrol. 1993, 7, 529) in children with IgA nephropathy (IgAN) and Schönlein-Henoch nephritis (HSN). Eight pts: 6 with IgAN, mean age 10.1 yrs and 2 with HSN aged 10.3 and 14.3 yrs were treated with use of alternate-day prednisone for 2.3 to 3.92 (mean 2.90 yrs). Renal biopsies were performed in all patients 2 to 72 (mean 16 mths) after onset and were graded according the classification of WHO. All pts had normal serum creatinine concentrations at presentation. 3 pts had proteinuria > 1 g/1.73 m2 per day at onset and 5 pts had macroscopic or microscopic haematuria and/or increased proteinuria and/or III grade WHO in renal biopsy. After treatment haematuria and proteinuria disappeared in 2 pts and decreased in 6 pts. Hypertension (2/8), hypercalciuria (2/8), mild weight gain (6/8) and low bone density in lumbar region (5/8) were observed during the treatment.


CONCLUSIONS
1. Long term alternate-day prednisone treatment according the protocol of Waldo allows to decrease haematuria and proteinuria in children with IgAN and HSN 2. Side effects of therapy were observed in 62.5% pts.
Szymanik-Grzelak
H
H
Katedra i Klinika Pediatrii i Nefrologii Akademi Medycznej w Warszawie.
Mizerska-Wasiak
M
M
Roszkowska-Blaim
M
M
D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001706:Biopsy; D002648:Child; D002675:Child, Preschool; D004334:Drug Administration Schedule; D005922:Glomerulonephritis, IGA / Q000188:drug therapy* / Q000473:pathology; D006417:Hematuria / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D011695:IgA Vasculitis / Q000150:complications*; D007668:Kidney / Q000473:pathology*; D009393:Nephritis / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use*; D011507:Proteinuria / Q000209:etiology / Q000517:prevention & control; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D011241:Prednisone